Breaking News, Collaborations & Alliances

IQVIA, Argenx Partner to Accelerate Clinical Development of VYVGART

Collaboration to support clinical development, regulatory, commercial and real-world evidence to accelerate the development of new indications for VYVGART.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

IQVIA entered an agreement with Argenx SE for the development of new indications for VYVGART (efgartigimod alfa fcab), an FDA-approved neonatal Fc receptor blocker for the treatment of generalized myasthenia gravis in adult patients who have a specific antibody receptor. Terms of the agreement were not disclosed.   The collaboration will support clinical development, regulatory, commercial and real-world evidence strategy to accelerate the development of new indications for VYVGART.   ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters